Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 June;59(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 June;59(2):220-7

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti
Per citare questo articolo

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

ORIGINAL ARTICLES  


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 June;59(2):220-7

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans

Ma C. 1, Wang X. 2, Shao M. 3, Zhao L. 4, Jiawei X. 5, Wu Z. 1, Wang H. 1

1 Department of Nuclear Medicine, Xinhua Hospital of Medical School, Shanghai Jiaotong University, Shanghai, Republic of China; 2 Nuclear Medicine, The First Affiliated Hospital, Sun Yatsen University, Guangzhou, Republic of China; 3 Department of Surgery, Linyi People’s Hospital, Linyi, Republic of China; 4 Nuclear Medicine, Linyi People’s Hospital, Linyi, Republic of China; 5 Shanghai Liqun Hospital, Shanghai, Republic of China


PDF  


AIM: Aim of the present study was to investigate the usefulness of 18F-FDG SPECT/CT in differentiated thyroid cancer (DTC) with elevated serum thyroglobulin (Tg) but negative iodine-131 scan.
METHODS: This retrospective review of patients with DTC recurrence who had 18F-FDG SPECT/CT and 18F-FDG PET/CT for elevated serum Tg but negative iodine-131 scan (March 2007-October 2012). After total thyroidectomy followed by radioiodine ablation, 86 consecutive patients with elevated Tg levels underwent 18F-FDG SPECT/CT or 18F-FDG PET/CT. Of these, 45 patients had 18F-FDG SPECT/CT, the other 41 patients had 18F-FDG PET/CT 3-4weeks after thyroid hormone withdrawal. The results of 18F-FDG PET/CT and SPECT/CT were correlated with patient follow-up information, which included the results from subsequent imaging modalities such as neck ultrasound, MRI and CT, Tg levels, and histologic examination of surgical specimens. The diagnostic accuracy of the two imaging modalities was evaluated.
RESULTS: In 18F-FDG SPECT/CT scans, 24 (24/45) patients had positive findings, 22 true positive in 24 patients, false positive in 2 patients, true-negative and false-negative in 6, 15 patients, respectively. The overall sensitivity, specificity, and accuracy of 18F-FDG SPECT/CT were 59.5%, 75% and 62.2%, respectively. Twenty six patients had positive findings on 18F-FDG PET/CT scans, 23 true positive in 26 (26/41) patients, false positive in 3 patients, true-negative and false-negative in 9, 6 patients, respectively. The overall sensitivity, specificity, and accuracy of 18F-FDG PET/CT were 79.3%, 81.8% and 78.1%, respectively. Clinical management changed for 13 (29%) of 45 patients by 18F-FDG SPECT/CT, 14 (34%) of 41 patients by 18F-FDG PET/CT including surgery, radiation therapy, or multikinase inhibitor.
CONCLUSION: Based on the retrospective analysis of 86 patients, 18F-FDG SPECT/CT has lower sensitivity in the diagnosis of DTC recurrence with elevated Tg and negative iodine-131scan to 18F-FDG PET/CT. The clinical application of FDG SPECT/CT is then limited and cannot replace PET/CT.

inizio pagina

Publication History

Per citare questo articolo

Ma C, Wang X, Shao M, Zhao L, Jiawei X, Wu Z, et al. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans. Q J Nucl Med Mol Imaging 2015 June;59(2):220-7. 

Corresponding author e-mail

wanghuishanghai@hotmail.com